Annamaria Zannoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Annamaria Zannoni has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ana Rita Brochado
Department of Microbiology, Biocenter, University of Würzburg, Würzburg, Germany
4 shared publications - Roberto Olayo-Alarcon
Department of Statistics, Ludwig-Maximilians-Universität München
4 shared publications - Christian Lorenz Muller
Department of Statistics, Ludwig-Maximilians-Universität München
3 shared publications - Cynthia Mira Sharma
Department of Molecular Infection Biology II, Institute of Molecular Infection Biology (IMIB), University of Würzburg, Germany
3 shared publications - Martin K. Amstalden
Department of Microbiology, Biocenter, Julius-Maximilians-Universität Würzburg
3 shared publications - Medina Bajramovic
Department of Statistics, Ludwig-Maximilians-Universität München, Munich, Germany
3 shared publications
Latest Publications
- Open Access
Human-targeted drugs impact antibiotic sensitivity and growth of Campylobacter jejuni
Antibiotic resistance is increasingly recognized as a major threat to global health, yet the contribution of non-antibiotics to this problem remains poorly defined. Here, we established a transcriptional chemical genomics approach to map how 2,415 host-relevant small molecules influence stress-responsive promoters and fitness of the foodborne pathogen Campylobacter jejuni. This screen uncovered widespread activation of the CmeABC efflux pump by diverse compounds, including several human-targeted drugs. Notably, ibuprofen, one of the most widely used non-steroidal anti-inflammatory drugs worldwide, induced efflux pump expression and thereby enhanced bacterial tolerance to ciprofloxacin. We also identified multiple commensal-sparing human-targeted drugs with growth-inhibitory activity against C. jejuni , highlighting opportunities for pathogen-targeted drug repurposing. Together, our findings reveal that non-antibiotic drugs can both promote resistance-associated phenotypes and selectively suppress pathogen growth. This underscores the need to consider collateral drug effects on bacterial physiology when designing strategies to curb the burden of antimicrobial resistance.
Open AccessHuman-targeted drugs impact antibiotic sensitivity and growth of Campylobacter jejuni
Antibiotic resistance is increasingly recognized as a major threat to global health, yet the contribution of non-antibiotics to this problem remains poorly defined. Here, we established a transcriptional chemical genomics approach to map how 2,415 host-relevant small molecules influence stress-responsive promoters and fitness of the foodborne pathogen Campylobacter jejuni. This screen uncovered widespread activation of the CmeABC efflux pump by diverse compounds, including several human-targeted drugs. Notably, ibuprofen, one of the most widely used non-steroidal anti-inflammatory drugs worldwide, induced efflux pump expression and thereby enhanced bacterial tolerance to ciprofloxacin. We also identified multiple commensal-sparing human-targeted drugs with growth-inhibitory activity against C. jejuni , highlighting opportunities for pathogen-targeted drug repurposing. Together, our findings reveal that non-antibiotic drugs can both promote resistance-associated phenotypes and selectively suppress pathogen growth. This underscores the need to consider collateral drug effects on bacterial physiology when designing strategies to curb the burden of antimicrobial resistance.
- Open Access
Human-targeted drugs extensively reshape regulatory networks controlling virulence and antibiotic resistance in Salmonella Typhimurium
Human-targeted drugs are increasingly recognized to affect bacterial physiology, yet their impact beyond growth inhibition, and the underlying molecular mechanisms, remain poorly understood. Here, we systematically mapped how chemically diverse host-associated compounds influence virulence and intrinsic antibiotic resistance in Salmonella enterica serovar Typhimurium. Using a high-throughput reporter approach, we quantified transcriptional response of 26 key stress promoters in Salmonella against 2,415 compounds, including FDA-approved drugs, food-derived molecules, and human metabolites. We found that non-antibiotic compounds induce transcriptional responses distinct from those elicited by antibiotics, uncovering a regulatory shift from general stress responses to compound-specific regulation driven by ligand-responsive MarR- and TetR-family regulators. In particular, more than 200 non-antibiotic drugs modulate virulence or intrinsic resistance pathways through the central regulators SlyA or RamR, respectively. By integrating our large-scale dataset with machine learning, we further defined chemical features associated with ramA transcriptional activation in Salmonella , and predicted ∼200 additional candidate inducers of intrinsic antibiotic resistance in this pathogen. Together, our results uncovered a large and previously unrecognized chemical landscape that reshapes bacterial stress responses through ligand-responsive regulatory mechanisms, with implications for how host-associated compounds influence pathogen virulence and antibiotic resistance. Highlights: Mapping the transcriptional response of key Salmonella stress pathways across a large chemical space shows that antibiotics and non-antibiotic compounds elicit distinct stress responses in Salmonella The activity of the virulence regulator SlyA is modulated by non-antibiotic compounds SlyA-inhibitors increase sensitivity to polymyxin B and decrease Salmonella virulence in cell culture Human-targeted drugs increase intrinsic antibiotic resistance via RamR-RamA in Salmonella Machine learning approach enables large-scale, out-of-sample prediction of human-targeted drugs inducing ramA expression in Salmonella
Open AccessHuman-targeted drugs extensively reshape regulatory networks controlling virulence and antibiotic resistance in Salmonella Typhimurium
Human-targeted drugs are increasingly recognized to affect bacterial physiology, yet their impact beyond growth inhibition, and the underlying molecular mechanisms, remain poorly understood. Here, we systematically mapped how chemically diverse host-associated compounds influence virulence and intrinsic antibiotic resistance in Salmonella enterica serovar Typhimurium. Using a high-throughput reporter approach, we quantified transcriptional response of 26 key stress promoters in Salmonella against 2,415 compounds, including FDA-approved drugs, food-derived molecules, and human metabolites. We found that non-antibiotic compounds induce transcriptional responses distinct from those elicited by antibiotics, uncovering a regulatory shift from general stress responses to compound-specific regulation driven by ligand-responsive MarR- and TetR-family regulators. In particular, more than 200 non-antibiotic drugs modulate virulence or intrinsic resistance pathways through the central regulators SlyA or RamR, respectively. By integrating our large-scale dataset with machine learning, we further defined chemical features associated with ramA transcriptional activation in Salmonella , and predicted ∼200 additional candidate inducers of intrinsic antibiotic resistance in this pathogen. Together, our results uncovered a large and previously unrecognized chemical landscape that reshapes bacterial stress responses through ligand-responsive regulatory mechanisms, with implications for how host-associated compounds influence pathogen virulence and antibiotic resistance. Highlights: Mapping the transcriptional response of key Salmonella stress pathways across a large chemical space shows that antibiotics and non-antibiotic compounds elicit distinct stress responses in Salmonella The activity of the virulence regulator SlyA is modulated by non-antibiotic compounds SlyA-inhibitors increase sensitivity to polymyxin B and decrease Salmonella virulence in cell culture Human-targeted drugs increase intrinsic antibiotic resistance via RamR-RamA in Salmonella Machine learning approach enables large-scale, out-of-sample prediction of human-targeted drugs inducing ramA expression in Salmonella
- Top Cited PapersOpen Access
- 10 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Pre-trained molecular representations enable antimicrobial discovery
The rise in antimicrobial resistance poses a worldwide threat, reducing the efficacy of common antibiotics. Determining the antimicrobial activity of new chemical compounds through experimental methods remains time-consuming and costly. While compound-centric deep learning models promise to accelerate this search and prioritization process, current strategies require large amounts of custom training data. Here, we introduce a lightweight computational strategy for antimicrobial discovery that builds on MolE (Molecular representation through redundancy reduced Embedding), a self-supervised deep learning framework that leverages unlabeled chemical structures to learn task-independent molecular representations. By combining MolE representation learning with available, experimentally validated compound-bacteria activity data, we design a general predictive model that enables assessing compounds with respect to their antimicrobial potential. Our model correctly identifies recent growth-inhibitory compounds that are structurally distinct from current antibiotics. Using this approach, we discover de novo, and experimentally confirm, three human-targeted drugs as growth inhibitors of Staphylococcus aureus. This framework offers a viable, cost-effective strategy to accelerate antibiotic discovery.
- 10 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Top Cited PapersOpen AccessPre-trained molecular representations enable antimicrobial discovery
The rise in antimicrobial resistance poses a worldwide threat, reducing the efficacy of common antibiotics. Determining the antimicrobial activity of new chemical compounds through experimental methods remains time-consuming and costly. While compound-centric deep learning models promise to accelerate this search and prioritization process, current strategies require large amounts of custom training data. Here, we introduce a lightweight computational strategy for antimicrobial discovery that builds on MolE (Molecular representation through redundancy reduced Embedding), a self-supervised deep learning framework that leverages unlabeled chemical structures to learn task-independent molecular representations. By combining MolE representation learning with available, experimentally validated compound-bacteria activity data, we design a general predictive model that enables assessing compounds with respect to their antimicrobial potential. Our model correctly identifies recent growth-inhibitory compounds that are structurally distinct from current antibiotics. Using this approach, we discover de novo, and experimentally confirm, three human-targeted drugs as growth inhibitors of Staphylococcus aureus. This framework offers a viable, cost-effective strategy to accelerate antibiotic discovery.
- Open Access
Statistical end-to-end analysis of large-scale microbial growth data with DGrowthR
Quantitative analysis of microbial growth curves is essential for understanding how bacterial populations respond to environmental cues. Traditional analysis approaches make parametric assumptions about the functional form of these curves, limiting their usefulness for studying conditions that distort standard growth curves. In addition, modern robotics platforms enable the high-throughput collection of large volumes of growth data, thus requiring strategies that can analyze large-scale growth data in a flexible and efficient manner. Here, we introduce DGrowthR , a statistical R framework and standalone app with a no-code interface for the integrative analysis of large growth experiments. DGrowthR comprises methods for data pre-processing and standardization, exploratory functional data analysis, and non-parametric modeling of growth curves using Gaussian Process regression. Importantly, DGrowthR includes a rigorous statistical testing framework for differential growth (DG) analysis. To illustrate the range of application scenarios of DGrowthR , we analyzed three large-scale bacterial growth datasets targeting distinct scientific inquiries. On an in-house dataset comprising more than 20, 000 growth curves of two pathogens that were subjected to chemical perturbations, DGrowthR enabled the discovery of compounds with significant growth inhibitory effects as well as compounds that induce non-canonical growth dynamics. On two publicly available perturbation datasets (> 100, 000 growth curves), DG analysis recovered reported adjuvants and antagonists of antibiotic activity, as well as bacterial genetic factors that determine susceptibility to specific antibiotic treatments. We anticipate DGrowthR to streamline the analysis of high-volume growth experiments, enabling researchers to make biological discoveries in a standardized and reproducible manner.
Open AccessStatistical end-to-end analysis of large-scale microbial growth data with DGrowthR
Quantitative analysis of microbial growth curves is essential for understanding how bacterial populations respond to environmental cues. Traditional analysis approaches make parametric assumptions about the functional form of these curves, limiting their usefulness for studying conditions that distort standard growth curves. In addition, modern robotics platforms enable the high-throughput collection of large volumes of growth data, thus requiring strategies that can analyze large-scale growth data in a flexible and efficient manner. Here, we introduce DGrowthR , a statistical R framework and standalone app with a no-code interface for the integrative analysis of large growth experiments. DGrowthR comprises methods for data pre-processing and standardization, exploratory functional data analysis, and non-parametric modeling of growth curves using Gaussian Process regression. Importantly, DGrowthR includes a rigorous statistical testing framework for differential growth (DG) analysis. To illustrate the range of application scenarios of DGrowthR , we analyzed three large-scale bacterial growth datasets targeting distinct scientific inquiries. On an in-house dataset comprising more than 20, 000 growth curves of two pathogens that were subjected to chemical perturbations, DGrowthR enabled the discovery of compounds with significant growth inhibitory effects as well as compounds that induce non-canonical growth dynamics. On two publicly available perturbation datasets (> 100, 000 growth curves), DG analysis recovered reported adjuvants and antagonists of antibiotic activity, as well as bacterial genetic factors that determine susceptibility to specific antibiotic treatments. We anticipate DGrowthR to streamline the analysis of high-volume growth experiments, enabling researchers to make biological discoveries in a standardized and reproducible manner.